119 related articles for article (PubMed ID: 37599043)
1. Chasing EGFR Mutations in the Plasma of Patients With Resected NSCLC: Lessons in the ADAURA Era.
Facchinetti F; Jänne PA; Tiseo M
J Thorac Oncol; 2023 Sep; 18(9):1118-1120. PubMed ID: 37599043
[No Abstract] [Full Text] [Related]
2. A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer.
Wu YL; Tsuboi M; John T; Grohe C; Majem M; Goldman JW; Laktionov K; Kim SW; Kato T; Vu HV; Lu S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Zeng L; Hodge R; Atasoy A; Rukazenkov Y; Herbst RS
Future Oncol; 2021 Dec; 17(35):4827-4835. PubMed ID: 34723634
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Review.
Passaro A; Mok TSK; Attili I; Wu YL; Tsuboi M; de Marinis F; Peters S
JAMA Oncol; 2023 Aug; 9(8):1124-1131. PubMed ID: 37166792
[TBL] [Abstract][Full Text] [Related]
4. Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.
Frampton JE
Target Oncol; 2022 May; 17(3):369-376. PubMed ID: 35713772
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological features and EGFR gene mutation status in elderly patients with resected non-small-cell lung cancer.
Nishii T; Yokose T; Miyagi Y; Daigo Y; Ito H; Isaka T; Imai K; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Tsuboi M; Nakayama H; Masuda M
BMC Cancer; 2014 Aug; 14():610. PubMed ID: 25152277
[TBL] [Abstract][Full Text] [Related]
6. EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features.
Lai Y; Zhang Z; Li J; Sun D; Zhou Y; Jiang T; Han Y; Huang L; Zhu Y; Li X; Yan X
Int J Mol Sci; 2013 Dec; 14(12):24549-59. PubMed ID: 24351833
[TBL] [Abstract][Full Text] [Related]
7. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.
Wu YL; John T; Grohe C; Majem M; Goldman JW; Kim SW; Kato T; Laktionov K; Vu HV; Wang Z; Lu S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Zeng L; Atasoy A; Herbst RS; Tsuboi M
J Thorac Oncol; 2022 Mar; 17(3):423-433. PubMed ID: 34740861
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma.
Nishii T; Yokose T; Miyagi Y; Daigo Y; Isaka T; Furumoto H; Ito H; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Nakayama H; Masuda M
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e204-e211. PubMed ID: 27349355
[TBL] [Abstract][Full Text] [Related]
9. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
10. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
11. [Predictive role of EGFR mutation status on postoperative prognosis in patients with resected lung adenocarcinomas].
Dong Y; Li Y; Peng H; Jin B; Huang A; Bai H; Xiong H; Han B
Zhongguo Fei Ai Za Zhi; 2013 Apr; 16(4):177-83. PubMed ID: 23601297
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapies for resectable lung adenocarcinoma: ADAURA opens for thoracic oncologic surgeons.
Jones DR; Wu YL; Tsuboi M; Herbst RS
J Thorac Cardiovasc Surg; 2021 Jul; 162(1):288-292. PubMed ID: 33691940
[TBL] [Abstract][Full Text] [Related]
13. Osimertinib in Resected
Wu YL; Tsuboi M; He J; John T; Grohe C; Majem M; Goldman JW; Laktionov K; Kim SW; Kato T; Vu HV; Lu S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Zeng L; Hodge R; Atasoy A; Rukazenkov Y; Herbst RS;
N Engl J Med; 2020 Oct; 383(18):1711-1723. PubMed ID: 32955177
[TBL] [Abstract][Full Text] [Related]
14. EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada.
Sara Kuruvilla M; Liu G; Syed I; Gwadry-Sridhar F; Sheffield BS; Sachdeva R; Pencz A; Zhan L; Hueniken K; Patel D; Balaratnam K; Khan K; Grant B; Noy S; Singh K; Liu L; Rakibuz-Zaman M; Moldaver D; Kate Shanahan M; Cheema PK
Lung Cancer; 2022 Nov; 173():58-66. PubMed ID: 36152478
[TBL] [Abstract][Full Text] [Related]
15. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial.
John T; Grohé C; Goldman JW; Shepherd FA; de Marinis F; Kato T; Wang Q; Su WC; Choi JH; Sriuranpong V; Melotti B; Fidler MJ; Chen J; Albayaty M; Stachowiak M; Taggart S; Wu YL; Tsuboi M; Herbst RS; Majem M
J Thorac Oncol; 2023 Sep; 18(9):1209-1221. PubMed ID: 37236398
[TBL] [Abstract][Full Text] [Related]
16. Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study.
Mordant P; Brosseau S; Milleron B; Santelmo N; Fraboulet-Moreau S; Besse B; Langlais A; Gossot D; Thomas PA; Pujol JL; Ricordel C; Madelaine J; Lamy R; Audigier-Valette C; Missy P; Blons H; Barlesi F; Westeel V;
Clin Lung Cancer; 2023 Jan; 24(1):1-10. PubMed ID: 36180314
[TBL] [Abstract][Full Text] [Related]
17. ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection.
Wu YL; Herbst RS; Mann H; Rukazenkov Y; Marotti M; Tsuboi M
Clin Lung Cancer; 2018 Jul; 19(4):e533-e536. PubMed ID: 29789220
[TBL] [Abstract][Full Text] [Related]
18. Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial.
Majem M; Goldman JW; John T; Grohe C; Laktionov K; Kim SW; Kato T; Vu HV; Lu S; Li S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Atagi S; Zeng L; Kulkarni D; Medic N; Tsuboi M; Herbst RS; Wu YL
Clin Cancer Res; 2022 Jun; 28(11):2286-2296. PubMed ID: 35012927
[TBL] [Abstract][Full Text] [Related]
19. High feasibility of liquid-based cytological samples for detection of EGFR mutations in Chinese patients with NSCLC.
Wu CY; Hou LK; Ren SX; Su B; Chen G
Asian Pac J Cancer Prev; 2014; 15(18):7885-9. PubMed ID: 25292082
[TBL] [Abstract][Full Text] [Related]
20. [Effectiveness of tyrosine kinase inhibitors against non-small cell lung cancer patients with postoperative recurrence harboring uncommon EGFR mutations].
Yang WJ; Gao YB; Qiu T; Wang YG; He J
Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):732-736. PubMed ID: 29061015
[No Abstract] [Full Text] [Related]
[Next] [New Search]
